In vivo p53 is multiply phosphorylated by dierent protein kinases suggesting a central role for phosphorylation in modulating p53 function. In addition, p53 was found to be associated with two protein kinases, p34 cdc2 and protein kinase CK2. Here we report the precise mapping of the interaction sites of p53 ± p34 cdc2 complexes. The p34 cdc2 binding site on human p53 maps to one distinct C-terminal site LQIRGRERFE (aa 330 ± 339) close to the corresponding phosphorylation site at serine 315. In order to test whether phosphorylation of p53 might in¯uence the binding of p53 to p34 cdc2 phosphorylation mutants of the C-terminus of p53, which mimick permanent phosphorylation, were tested on their ability to bind to p34 cdc2 in vitro. Substitution of serine 315 (the p34 cdc2 phosphorylation site) with aspartic acid had only little eect on complex formation whereas an exchange of serine 392 (the protein kinase CK2 phosphorylation site) to aspartic acid resulted in a signi®cant reduced relative binding anity of p53 to p34 cdc2 . The same result was obtained when the Cterminus of p53 was phosphorylated by puri®ed protein kinase CK2 prior to examination of complex formation. In addition, the speci®city of the complex formation has been checked by competition experiments with full length p53 proteins and the in¯uence of cyclin B on complex formation was examined.
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Introduction
All activities in a cell rely on the integrity of its genetic information and require a balance of growth and division. This is maintained by dierent feedback controls termed checkpoints which respond to various cellular conditions (Hartwell and Weinert, 1989; Hartwell and Kastan, 1994) . In higher eucaryotes the tumor suppressor protein p53 was found to play an important role in checkpoint control (Jacks and Weinberg, 1996) which is mirrored by the fact that mutation or deletion of the p53 gene is a frequent event in the majority of human tumours and favours malignancy (Harvey and Levine, 1991; Lane and Benchimol, 1990; Selter and Montenarh, 1994) . As a transcriptional activator p53 is responding to a variety of DNA-damaging agents by transactivating expression of proteins which control cellular growth resulting either in growth arrest or apoptosis (Kuerbitz et al., 1992; Lee and Bernstein, 1993; Kastan, 1993) . The best known example for a downstream mediator of growth suppressing activity is the p21 WAF1 gene product which was found to inhibit cyclin-dependent kinases (cdks) selectively (El-Deiry et al., 1993 , 1994 . In the absence of p21
WAF1 when the transactivational function of p53 for p21
WAF1 is obsolete DNA damaged cells arrest in a G2-like state and then undergo additional S phases without intervening normal mitoses indicating that an important checkpoint is not functioning (Waldman et al., 1996; Jacks and Weinberg, 1996) . In addition, p21 WAF1 has also been found to bind to the replication factor PCNA (proliferating-cell nuclear antigen) resulting in an inhibition of DNA synthesis (Mercer et al., 1991; Chen et al., 1995 Chen et al., , 1996 . In vivo wild-type and mutant p53 is multiply phosphorylated at several sites suggesting a control of p53 function by phosphorylation (Bischo et al., 1990; Meek and Street, 1992; StuÈ rzbecher et al., 1990; Lees-Miller et al., 1992; Ullrich et al., 1993; Milne et al., 1992b Milne et al., , 1994 .
There is an increasing body of evidence that the carboxy terminal domain of p53 is crucial for the regulation of the DNA binding ability of p53 (Hupp et al., 1992; Hall et al., 1996; Hupp and Lane, 1994) . The carboxy terminus contains sites for phosphorylation by several kinases. Among these kinases is the protein kinase CK2 which was found in complex with mutant and wild-type p53 in transformed cells (Kraiss et al., 1990; Herrmann et al., 1991; Lorenz et al., 1992) . Binding studies of p53 and protein kinase CK2 revealed that the region between amino acids 287 and 340 on the polypeptide chain of human p53 is critical for the binding to the b-subunit of protein kinase CK2 whereas neither phosphorylation at the p34 cdc2 site (serine 315) nor at the CK2 site (serine 392) did in¯uence complex formation of p53 and the b-subunit of protein kinase CK2 (Wagner et al., 1994; Appel et al., 1995) . Both phosphorylation events, however, seem to be involved in the activation of p53. There is some controversy regarding the importance of CK2 phosphorylation of p53 in vivo. Whereas in one report the replacement of the corresponding serine phosphorylated by protein kinase CK2 with an alanine residue abolished p53 suppressor function (Milne et al., 1992a) there was found in another that the growth suppressor function of p53 is not aected (Fiscella et al., 1994) . Furthermore, it has been demonstrated that mutations at the corresponding CK2 site of p53 did not alter its transactivation properties using a reporter construct carrying 13 copies of the p53 consensus binding site whereas transrepression activities of p53 appeared to be regulated by CK2 phosphorylation (Hall et al., 1996) . In addition, it could be demonstrated in vitro that phosphorylation by protein kinase CK2 favours the transition of a latent p53 to an activated form capable of sequence-speci®c transcriptional activation (Hupp et al., 1992; Hupp and Lane, 1994) .
Another phosphorylation site at serine 315 has drawn a lot of attention since this site was found to be phosphorylated in vivo and could be phosphorylated by S and G2/M cyclin-dependent kinases in vitro (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Wang and Prives, 1995) . Evidence that cyclin-dependent kinases are responsible for phosphorylation of Ser-315 in vivo (Bischo et al., 1990) stems from ®ndings that the phosphorylation state of p53 varies within the cell cycle and that immunodepletion of p34 cdc2 from cell lysates removes the kinase activity which phosphorylates Ser-315 (Bischo et al., 1990; StuÈ rzbecher et al., 1990) . Moreover, various groups reported that p53 could be found in complex with cyclin-dependent kinases (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Milner et al., 1990 ) and the corresponding phosphorylation at serine 315 markedly stimulates sequence-speci®c DNA binding of p53 and confers binding site preference on p53 (Wang and Prives, 1995) .
Here we report the precise mapping of the interaction sites of p53 ± p34 cdc2 complexes. The p34 cdc2 binding site on human p53 maps to the C-terminus close to the corresponding phosphorylation site at serine 315. Substitution of serine 315 (the p34 cdc2 phosphorylation site) with aspartic acid had only little eect on complex formation whereas an exchange of serine 392 (the protein kinase CK2 phosphorylation site) to aspartic acid resulted in a signi®cant reduced relative binding anity of p53 to p34 cdc2 . The same result was obtained when the Cterminus of p53 was phosphorylated by puri®ed protein kinase CK2 prior to examination of complex formation. In addition, the speci®city of the complex formation as well as the in¯uence of Cyclin B was examined. These data suggest a ®ne tuning mechanism of p53 activation by at least two independent phosphorylation events.
Results

The p34
cdc2 binding site maps to a new domain within the C-terminus of p53
In vivo wild-type and mutant p53 is multiply phosphorylated at its carboxy terminal domain (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Meek and Street, 1992) . In addition, p53 was found to be associated with protein kinases p34 cdc2 (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Milner et al., 1990; Fuchs et al., 1995) and protein kinase CK2 (Kraiss et al., 1990; Herrmann et al., 1991; Lorenz et al., 1992) suggesting that cell cycle dependent phosphorylation might control p53 in a ®ne tuning fashion. For the analysis of the p53 ± p34 cdc2 interaction we decided to use an approach which had already proven successful for the mapping of the interaction sites of p53 with the regulatory b-subunit of protein kinase CK2 (Wagner et al., 1994; Appel et al., 1995) . Since various cyclin-dependent kinases are capable of phosphorylation of p53 in vitro and sequences of the corresponding cyclins vary considerably we decided to concentrate on the catalytic subunit p34 cdc2 which shows a high degree of conservation among the regulatory subunits of cyclin dependent kinases. On the other hand we concentrated on the C-terminus of human p53 since this was found to be as ecient as full length p53 in terms of phosphorylation by p34 cdc2 (Bischo et al., 1990; StuÈ rzbecher et al., 1990) . In order to use p34 cdc2 as a probe for binding assays on p53 a sequenced wild-type p34 cdc2 cDNA, originally isolated from HeLa cells (described elsewhere), was modi®ed to encode for an arti®cial phosphorylation site for cAMP dependent heart muscle kinase at the N-terminus. This modi®ed p34 cdc2 cDNA was cloned into the bacterial expression vector pQE30 (Qiagen) to introduce a tag of six additional histidine residues at the N-terminus of expressed proteins. This allows a rapid single step puri®cation of recombinant p34 cdc2 protein on a Ni 2+ -NTA agarose column and radioactive labelling of puri®ed protein with commercially available heart muscle kinase (Sigma) as described previously (Wagner et al., 1994; Appel et al., 1995) . After puri®cation of p34 cdc2 on a Ni 2+ ± NTA agarose column phosphorylation of puri®ed p34 cdc2 protein by cAMP ± dependent heart muscle kinase and [ 32 P-g-]ATP resulted in one exclusive radioactive labelled protein as judged by autoradiography whose identity was veri®ed by immunoblotting using a speci®c p34 cdc2 polyclonal antibody as shown in Figure 1 . After the expression, puri®cation and ecient labelling of the p34 cdc2 protein we tested its binding ability to a set of dierent C-terminal peptides of human p53 which had already proven useful for the mapping of p53 with protein kinase CK2 (Appel et al., 1995) . For the West-Western blot analysis total lysates of E. coli cells expressing the C-terminal fragments (A, amino acids 264 ± 393, B, amino acids 287 ± 293, C, amino acids 340 ± 393) were subjected to SDS ± polyacrylamide gel electrophoresis without boiling prior to loading the gel. After renaturation the proteins were transferred to nitrocellulose ®lters and either probed with puri®ed and labelled p34 cdc2 protein or to control expression reacted with PAb421 (Harlow et al., 1981) as described previously (Appel et al., 1995) . Figure 2a shows the immunoblot analysis where we controlled the expression of the C-terminal fragments of p53. As shown in Figure . Equal amounts of total lysates of E. coli cells transformed with plasmid pQE30-p34 cdc2 were subjected to 15% SDS-polyacrylamide gel electrophoresis before (a) and after induction (b) of protein expression. Lane c shows the puri®ed p34 cdc2 protein after Ni 2+ -anity puri®cation and dialysis. The puri®ed p34 cdc2 protein was probed with a polyclonal antibody raised against p34 cdc2 to verify the nature of the puri®ed protein as shown (d).
Fine mapping P Wagner et al protein bound to the C-terminal fragments aa 264 ± 393 and aa 287 ± 393 whereas the C-terminal fragment aa 340 ± 393 failed to bind to the p34 cdc2 protein indicating that the binding region lies within a domain spanning amino acids 287 ± 340. The possibility of labelling of the C-terminal peptide by residual traces of cAMP-dependent kinase could be excluded by doing a control experiment lacking puri®ed p34 cdc2 (data not shown). The identi®ed region spanning amino acids 287 ± 340 of p53 had previously been shown to be critical for the interaction of p53 with the b-subunit of protein kinase CK2 (Appel et al., 1995) . Since the systematic screening of series of short peptide sequences has become a powerful approach for characterising protein-protein interactions we used a synthetic approach to narrow down the p34 cdc2 binding domain on the C-terminus of p53 by means of the SPOTs method. This method allows the rapid solid phase synthesis of peptides in equal molar quantities immobilised on a cellulose membrane in a format suitable for systematic analysis of proteinprotein interactions or antibody epitope mapping. This method had already proven successful for the mapping of the p53 binding site on the tms1 protein (Wagner, 1994; Wagner et al., 1995a) and vice versa (Wagner et al., 1995b) as well as the precise de®nition of the epitopes of three dierent monoclonal antibodies raised against recombinant tms1 protein (Wagner et al., 1994b; Schneider et al., 1995) . First we synthesized a set of 11 overlapping peptides of 10 amino acid long sections of the p53 primary amino acid sequence spanning the p34 cdc2 binding region from amino acid 285 ± 344. After blocking the ®lter was probed with labelled puri®ed p34 cdc2 protein, washed and subjected to autoradiography. As shown in Figure  3 this resulted in binding of p34 cdc2 protein to three dierent consecutive peptides with a remarkable speci®city indicating a strong interaction between the p34 cdc2 protein and the p53-derived peptides. No such signals were obtained when puri®ed p34 cdc2 protein was omitted (data not shown). Since these identi®ed peptides overlapped by the sequence LQIRGRERFE (aa 330 ± 339) we concluded that the p34
cdc2 binding domain appears to be a single site on the polypeptide chain of p53.
Phosphorylation by protein kinase CK2 aects association of p53 and p34 cdc2
The carboxy terminal domain of human p53 spanning amino acids 264 ± 393 contains at least two phosphorylation sites, one for p34 cdc2 kinase at amino acid 315 and another one for protein kinase CK2 at amino acid 392. In order to analyse the eect of phosphorylation at these sites on the association of p34 cdc2 and p53 we repeated the West-Western blot analysis with a set of dierent C-terminal mutant fragments of p53. In an attempt to mimick constitutive phosphorylation at the particular amino acid positions single serine residues were changed to aspartic acid or in the case of the double mutant both serines at position 315 and 392 were changed to aspartic acid as described previously (Appel et al., 1995) . For the West-Western blot analysis equal amounts of lysates of E. coli cells expressing C-terminal fragments (CT-WT ± wildtype; CT-DS ± Asp-315, Ser-392; CT-SD ± Ser-315, Asp-392 or CT-DD ± Asp-315, Asp-392) were subjected to 15% SDS-polyacrylamide gel electrophoresis, renatured and transferred onto a nitrocellulose ®lter which was probed with puri®ed radioactive labelled p34 cdc2 protein. Figure 4 shows the result of this West ± Western blot analysis. Whereas the introduction of an aspartic acid at position 315 had only little eect on the association of p34 cdc2 and p53, the change of serine 392 to aspartic acid showed a signi®cant reduction in the relative binding anity of p34 cdc2 and p53 in the case of the single mutant (CT-SD) as well as in the case of the double mutant (CT-DD).
In order to verify this result we phosphorylated the C-terminal wild-type fragment of p53 with puri®ed protein kinase CK2 and unlabelled ATP and analysed this together with the same amount of unphosphorylated C-terminal wild-type fragment in a West-Western blot analysis. Figure 5 shows the result of this experiment which is in good agreement to the results , washed and subjected to autoradiography Figure 3 West-Western blot analysis on p53 peptides with p34 cdc2 as a probe. The membrane carrying the p53 peptide library in equimolar quantities was probed with puri®ed radioactive labelled p34 cdc2 protein, washed and subjected to autoradiography To convince ourselves that the observed dierences of the apparent relative binding anities of the Cterminal fragments of p53 for p34 cdc2 are not due to a dierent renaturation behaviour we decided to repeat the West-Western blot analysis with full length p53 and the corresponding p53 D392 full length mutant. Bacterially expressed full length p53 had been previously shown to be capable for DNA binding which can be activated by phosphorylation with protein kinase CK2 and to form proper tetrameric structures (Hupp and Lane, 1994) . For this purpose the full length p53 cDNAs were cloned into the pQE30 vector (Qiagen) resulting in expression of p53 proteins carrying additional six histidine residues fused to the N-terminus. Wild-type and D392 full length proteins were puri®ed under native conditions by Ni 2+ -chelate anity chromatography as described and applied directly after puri®cation onto nitrocellulose ®lters using a slot blot device (Schleicher & SchuÈ ll) to avoid the renaturation step before incubating with a radioactive labelled, puri®ed p34 cdc2 protein.
As it is shown in Figure 6 this resulted in a decreased relative binding anity in the case of the D392 full length p53 mutant when compared to the wild-type full length p53. This is in good agreement with our data obtained with the Cterminal fragments of p53 after renaturation indicating that it is justi®ed to use the C-terminal fragments as well as the method to determine relative binding anities.
On the other hand to demonstrate the speci®city of the p53 ± p34 cdc2 interaction we performed competition assays by adding an excess of puri®ed C-terminal fragment of p53 spanning amino acids 264 ± 393 or a peptide comprising the mapped binding site. As it is shown in Figure 6 in both cases this resulted in a complete suppression of complex formation between p53 and p34 cdc2 indicating that the observed complex formation is speci®c. Since cyclin-dependent kinases are not active unless complexed with cyclins we examined the complex formation of full length wildtype and D392 mutant p53 in the presence of an excess of puri®ed Cyclin B protein. For this purpose we isolated a Cyclin B cDNA from HeLa cells by means of RT ± PCR (described elsewhere) and cloned it into the pQE30 vector (Qiagen) for expression E. coli and rapid puri®cation on a Ni 2+ -chelate column. As it is shown in Figure 5 the addition of Cyclin B in our described binding assay had no decreasing eect on the relative binding anity of p53 for p34 cdc2 suggesting that the p34 cdc2 -Cyclin B interaction is not leading to a steric hindrance for p53 ± p34 cdc2 complex formation. Furthermore, also in this case we saw a reduction in the interaction between p53 and p34 cdc2 when using the phosphorylation mutant D392. Figure 4 West-Western blot analysis on phosphorylation mutants of p53. Equal amounts of total lysates of E. coli cells expressing C-terminal fragments CT ± WT (wild-type aa 264 ± 393), CT ± DS (Asp-315, Ser-392), CT ± SD (Ser-315, Asp-392) or CT ± DD (Asp-315, Asp-392) were subjected to 15% SDS ± polyacrylamide gel electrophoresis. Proteins were renatured and transferred onto a nitrocellulose ®lter which was probed with puri®ed radioactive labelled p34 cdc2 , washed and subjected to autoradiography Figure 5 p34 cdc2 binding to phosphorylated and unphosphorylated C-terminus of p53. 20mg puri®ed C-terminal wild-type fragment of p53 spanning amino acids 264 ± 393 was phosphorylated with puri®ed protein kinase CK2 using 32 P-g-ATP. Under these conditions the amount of incorporation of [ 32 P] ranged about 80% as judged by Cerenkov counting. Same amounts of cold labelled and unphosphorylated fragments were subjected to 15% SDS-polyacrylamide gel electrophoresis. Proteins were renatured and transferred onto a nitrocellulose ®lter which was probed with puri®ed radioactive labelled p34 cdc2 , washed and subjected to autoradiography Figure 6 Speci®city and in¯uence of Cyclin B. For the competition experiments either 10mg bacterially expressed and puri®ed full length wild type p53 or full length D392 mutant p53 were applied directly onto nitrocellulose ®lters using a slot blot device (Schleicher & SchuÈ ll). After blocking the nitrocellulose ®lters were probed with radioactive labelled and puri®ed p34 cdc2 protein and after several washings subjected to autoradiography to determine the amount of binding. In case of competition experiments a 15-fold molar excess of Cyclin B, C-terminal fragment of p53 or binding peptide was used 
Discussion
In this report we describe the detailed analysis of the association of p34 cdc2 and p53. Evidence for the importance of this interaction comes from ®ndings of several groups reporting complexes of p53 and p34 cdc2 (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Milner et al., 1990; Fuchs et al., 1995) . Moreover, p53 was found to be phosphorylated at several carboxy-terminal sites in vivo and it could be shown that the phosphorylation of p53 varies through the cell cycle in response to p34 cdc2 phosphorylation (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Fuchs et al., 1995) . In vitro various cyclindependent protein kinases like p34 cdc2 are capable to phosphorylate human p53 at serine 315 eciently (Bischo et al., 1990; StuÈ rzbecher et al., 1990; Wang and Prives, 1995) . Such phosphorylation can cause a distinctive conformational change of p53 favouring the transition of a latent to an activated p53 with a markedly stimulated sequence-speci®c DNA binding ability and binding site preference (Wang and Prives, 1995) .
In order to identify domains involved in p53 ± p34 cdc2 interaction we have chosen an approach which had already proven successful in the analysis of the interaction of p53 with protein kinase CK2 (Wagner et al., 1994a; Appel et al., 1995) . Using a set of Cterminal deletion mutants we were able to identify the region spanning from amino acid 287 ± 340 as critical for p53 ± p34 cdc2 interaction. This region was further narrowed down by means of West-Western blot analysis using a peptide library derived from the primary amino acid sequence of the C-terminus of human p53. This resulted in binding of p34 cdc2 to three consecutive p53-derived peptides which overlapped by the sequence LQIRGRERFE (aa 330 ± 339) residing close to the corresponding phosphorylation site at serine residue 315. Fortunately, there are structural data of the C-terminal domain of p53 available allowing a further evaluation of our results. Recently, it has been established that amino acids 319 ± 360 constitute the minimal tetramerization unit of p53 and the three-dimensional structure of the tetramerization domain has been resolved by multidimensional NMR (Clore et al., 1994) . The domain was found to form a 20 kDa symmetric tetramer made up from a dimer of dimers which comprise two antiparallel helices linked by an antiparallel b-sheet. The turn spanning amino acids 330 ± 337 which links the helices to the b-sheet is likely to be exposed to the surface of p53 and therefore accessible for protein-protein interactions (Clore et al., 1994) . This is in good agreement with our identi®ed p34 cdc2 binding domain spanning from amino acid 334 ± 339. Interestingly, the same domain has been identi®ed previously as binding domain of the ®ssion yeast protein tms1 (Wagner, 1994; Wagner et al., 1995b) which had been isolated as a multi copy suppressor of a p53-induced growth arrest in ®ssion yeast (Wagner et al., 1991 (Wagner et al., , 1993 . In addition, the corresponding region was found to be critical for the association of the b-subunit of protein kinase CK2 with p53 suggesting the identi®cation of an important new functional domain on the p53 protein (Wagner et al., 1994a; Appel et al., 1995) . This is further supported by recent ®ndings that the adenoviral AdE4orf6 protein was shown to interact with p53 within amino acids 318 ± 360 of p53 and to block the p53-mediated transcriptional activation by preventing the interaction of p53 with TAFII31, a component of transcription factor IID (TFIID), within its N-terminus (Dobner et al., 1996) . On the other hand three point mutations (Leu330?His, Gly334?Val and Arg335?Cys) (Liu et al., 1994; D'Amico et al., 1992; Nishida et al., 1993) found in human tumours map to the identi®ed p34 cdc2 binding region (aa 330 ± 339) which is remarkable since apart from stop and frameshift mutations only few point mutations within the C-terminus of p53 have been reported. These point mutations are located within the mentioned turn region and it was reasoned that these point mutations are potentially destabilizing the tetrameric structure of p53 since they are located at sites nearby the helix and b-sheet interactions (Clore et al., 1994) .
Another protein which was found in complex with p53 and to phosphorylate p53 is the protein kinase CK2 (Kraiss et al., 1990; Hermann et al., 1991; Lorenz et al., 1992) . In this case we were able to demonstrate that the region between amino acids 287 and 340 on the polypeptide chain of p53 is critical for binding of p53 to the b-subunit of CK2 but not to the a-subunit of CK2 alone (Wagner et al., 1994a; Appel et al., 1995) . Neither phosphorylation at the p34 cdc2 site (aa315) nor at the CK2 site (aa392) were found to in¯uence binding of p53 to the b-subunit of CK2 (Appel et al., 1995) . Since p53 is found to be phosphorylated at both sides in vivo we addressed the question whether the same is the case for binding of p53 to p34 cdc2 . As judged from our results obtained with a set of C-terminal phosphorylation mutants we found a striking dierence. Substitution of serine 315 (the p34 cdc2 phosphorylation site) with aspartic acid, which is thought to mimick constitutive phosphorylation, had only little eect on p53 ± p34 cdc2 binding whereas the exchange of serine 392 to aspartic acid at the protein kinase CK2 site resulted in a profound reduced relative binding anity of p53 for p34 cdc2 . This result could be veri®ed when we phosphorylated the corresponding C-terminal wild-type fragment by protein kinase CK2 and repeated the binding experiment. Also in this case a signi®cant reduction in the relative binding anity of p53 towards p34 cdc2 was noted when compared to an unphosphorylated fragment suggesting a ®ne tuning mechanism of p53 by phosphorylation.
The signi®cance of phosphorylation of p53 by protein kinase CK2 has been clearly demonstrated for the sequence-speci®c DNA binding where a bacterially expressed, unphosphorylated p53 showed a low anity for its DNA consensus sequence which could be strongly activated when p53 was phosphorylated by protein kinase CK2 (Hupp et al., 1992; Hall et al., 1996; Hupp and Lane, 1994) . On the other hand, phosphorylation of p53 by cyclin-dependent kinases was found to enhance the DNA binding capacity as well (Wang and Prives, 1995) . However, in addition to the enhancement of the DNA binding capacity phosphorylation of p53 by cyclin-dependent kinases in¯uenced the selective binding to its cognate consensus sequence present in the p21 WAF1 or GADD45 genes, whereas binding of p53 to its DNA consensus sequence in the ribosomal gene cluster or muscle creatine kinase gene was hardly in¯uenced.
Fine mapping P Wagner et al
Furthermore, the interaction of unphosphorylated p53 with antibody PAb421 dramatically increased its binding to both the ribosomal gene cluster (RGC) as well as the bax1 gene whereas additional phosphorylation of p53 led to an even more pronounced binding to the RGC sequence and the binding to the bax1 gene was reduced. This clearly indicates that these eects are clearly separable and it has been proposed that dierential phosphorylation and differential response to phosphorylation may be a mean to prevent simultaneous activation of genes with contradictory activities (Hecker et al., 1996) . Our ®ndings that phosphorylation by protein kinase CK2 leads to a reduced binding of p34 cdc2 to p53 might mirror a ®ne tuning mechanism of an enzyme/subtrate association where the mapped binding region of amino acids 330 ± 339 might play the part of a nucleation point for recruiting the p34 cdc2 kinase to p53 which can be regulated through protein kinase CK2 by phosphorylation of p53. Since both phosphorylation events found in vivo are seemingly activating sequence-speci®c DNA binding of p53 (Hupp et al., 1992; Hupp and Lane, 1994) , however, only phosphorylation by cdks is confering binding site preference (Wang and Prives, 1995) , the observed change in relative binding anity might exclusively account for the speci®city of p53 function.
Materials and methods
Expression and puri®cation of recombinant proteins
The p34 cdc2 cDNA was modi®ed by PCR to introduce appropriate BamHI and HindIII restriction sites, respectively. 5' primers contained in addition a cAMP-dependent protein kinase site (Li et al., 1989) and the ampli®ed fragment was cloned into the pQE30 vector (Qiagen) to produce plasmids pQE30-p34 cdc2 which was checked by sequencing. The plasmids for the C-terminal fragments of p53 were as described previously (Appel et al., 1995) . For puri®cation cells from 1 1 bacterial cultures were pelleted, washed with 50 mM Tris-HCl, pH 8.0, 0.1 M NaCl and resuspended in 6 M guanidine hydrochloride, 0.1 M sodium phosphate, pH 8.0 and lysed overnight at 48C. After precipitating cellular debris the cleari®ed supernatants were applied onto Ni 2+ -NTA agarose (Qiagen). The chelate resins were washed with 10 volumes each of lysing buer. Bound proteins were eluted with lysing buer, pH 4.0, and dialyzed against 20 mM Tris-HCl, pH 8.0, 300 mM KCl, 5 mM MgCl2, 0.1% Tween 20 to allow refolding and proteins were analysed by SDS ± polyacrylamide gel electrophoresis and checked by immuno blot analysis as described previously (Wagner et al., 1994) .
In case of full length wild type D392 mutant p53 as well as Cyclin B pelleted cells from 1 1 bacterial cultures were soni®cated in dialysis buer and cleari®ed supernatants were applied onto Ni 2+ -chelate agarose (Qiagen) and washed with 10 volumes of dialysis buer containing 10 mM imidazole in addition. Bound proteins were eluted in dialysis buer containing 200 mM imidazole, dialyzed against 20 mM TrisHCl, pH 8.0, 300 mM KCl, 0.1% Tween 20 to allow refolding and proteins were analysed by SDS ± polyacrylamide gel electrophoresis and checked by immuno blot analysis as described previously (Wagner et al., 1994a) .
SDS-polyacrylamide gel electrophoresis and Western blot analysis
Total bacterial lysates prepared by resuspending cell pellets of transformed E. coli with SDS sample buer (130 mM Tris-HCl, pH 6.8, 0.02% (w/v) bromophenolblue, 20% (v/ v) glycerol, 4% (w/v) SDS) and soni®cation, or puri®ed recombinant proteins were analysed by 15% SDS ± polyacrylamide gel electrophoresis. Protein detection was carried out by Coomassie blue staining or by Western blot analysis transferring non-®xed proteins onto nitrocellulose membranes. Blots were developed using the monoclonal p53 antibody PAb421 (Harlow et al., 1981) followed by the ECL method (Amersham) according to the manufacturer's recommendations.
In vitro kinase reactions
Usually 10mg of C-terminal p53 protein was used in protein kinase reactions with 1 mU protein kinase CK2 holoenzyme (1 U is the amount of protein kinase catalyzing the transfer of 1mmole phosphate/min. to the speci®c substrate). The standard reaction was carried out in 25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 10 mM MgCl 2 , 1 mM DTT and 50mM [ 32 P-g-]ATP (spec. activity 2000 c.p.m./ pmol). For the evaluation of [ 32 P] incorporation the radioactive bands determined by autoradiography were cut out and measured by Cerenkov counting.
For labelling of the p34 cdc2 protein, carrying an additional phosphorylation site within its N-terminus, about 30mg of recombinant puri®ed protein was labelled for 30 min at 378C with heart muscle cAMP dependent protein kinase (SIGMA) according to the manufacturer's recommendations.
West-Western blot analysis
Total lysates of C-terminal p53 peptides expressing E. coli cells were subjected to SDS ± polyacrylamide gel electrophoresis without boiling prior to loading the gel. After renaturation in 200 ml 106PBS at 48C for 1 h proteins were transferred onto nitrocellulose ®lters. Filters were blocked for 1 h at 48C with dialysis buer and probed with labelled puri®ed p34 cdc2 protein for 1 h at 48C under gentle agitation. After washing two times with dialysis buer ®lters were subjected to autoradiography. In case of full length p53 renaturation was avoided by applying samples directly onto nitrocellulose ®lters using a slot blot device (Schleicher & SchuÈ ll). In competition assays a 15-fold molar excess of Cyclin B, C-terminal wild type fragment of p53 or binding peptide (GEYFTLQIRGRERFEMFREL) was added to the incubation mix.
Peptide synthesis according to the SPOT method A set of 11 peptides of 10 amino acid long sections of amino acid 285 ± 344 of the C-terminus of p53 that consecutively overlapped by ®ve amino acids were synthesized by means of the SPOT method (CRB, England) according to the manufacturer's recommendations allowing to obtain equal molar quantities in the mmolar range for peptides.
